153 related articles for article (PubMed ID: 22190957)
1. Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?
Diav-Citrin O; Ornoy A
Obstet Gynecol Int; 2012; 2012():698947. PubMed ID: 22190957
[TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy.
Ornoy A; Koren G
Semin Fetal Neonatal Med; 2014 Jun; 19(3):188-94. PubMed ID: 24321501
[TBL] [Abstract][Full Text] [Related]
3. Selective Serotonin Reuptake Inhibitors during Pregnancy: Do We Have Now More Definite Answers Related to Prenatal Exposure?
Ornoy A; Koren G
Birth Defects Res; 2017 Jul; 109(12):898-908. PubMed ID: 28714608
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes.
Jefferies AL;
Paediatr Child Health; 2011 Nov; 16(9):562-3. PubMed ID: 23115498
[TBL] [Abstract][Full Text] [Related]
5. [Current evaluation of teratogenic and fetotoxic effects of psychotropic drugs].
Watanabe O
Seishin Shinkeigaku Zasshi; 2014; 116(12):996-1004. PubMed ID: 25823351
[TBL] [Abstract][Full Text] [Related]
6. Treatment with Selective Serotonin Reuptake Inhibitors in the Third Trimester of Pregnancy : Effects on the Infant.
Nordeng H; Spigset O
Drug Saf; 2005 Jul; 28(7):565-581. PubMed ID: 27722970
[TBL] [Abstract][Full Text] [Related]
7. Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Major Malformations: The Importance of Serotonin for Embryonic Development and the Effect of Serotonin Inhibition on the Occurrence of Malformations.
Bérard A; Levin M; Sadler T; Healy D
Bioelectricity; 2019 Mar; 1(1):18-29. PubMed ID: 34471805
[TBL] [Abstract][Full Text] [Related]
8. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis.
Kornum JB; Nielsen RB; Pedersen L; Mortensen PB; Nørgaard M
Clin Epidemiol; 2010 Aug; 2():29-36. PubMed ID: 20865100
[TBL] [Abstract][Full Text] [Related]
9. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study.
Jimenez-Solem E; Andersen JT; Petersen M; Broedbaek K; Jensen JK; Afzal S; Gislason GH; Torp-Pedersen C; Poulsen HE
BMJ Open; 2012; 2(3):. PubMed ID: 22710132
[TBL] [Abstract][Full Text] [Related]
10. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
[TBL] [Abstract][Full Text] [Related]
11. SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.
Hosenbocus S; Chahal R
J Can Acad Child Adolesc Psychiatry; 2011 Feb; 20(1):60-7. PubMed ID: 21286371
[TBL] [Abstract][Full Text] [Related]
12. Selective serotonin reuptake inhibitors and pregnancy: A review of maternal, fetal and neonatal risks and benefits.
Marchocki Z; Russell NE; Donoghue KO
Obstet Med; 2013 Dec; 6(4):155-8. PubMed ID: 27656248
[TBL] [Abstract][Full Text] [Related]
13. Use of selective serotonin reuptake inhibitor antidepressants in pregnancy does carry risks, but the risks are small.
Casper RC
J Nerv Ment Dis; 2015 Mar; 203(3):167-9. PubMed ID: 25714254
[TBL] [Abstract][Full Text] [Related]
14. Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure.
Corti S; Pileri P; Mazzocco MI; Mandò C; Moscatiello AF; Cattaneo D; Cheli S; Baldelli S; Pogliani L; Clementi E; Cetin I
Front Pediatr; 2019; 7():309. PubMed ID: 31403037
[No Abstract] [Full Text] [Related]
15. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer.
Ashbury JE; Lévesque LE; Beck PA; Aronson KJ
Front Oncol; 2012; 2():177. PubMed ID: 23227451
[TBL] [Abstract][Full Text] [Related]
16. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis.
Nikfar S; Rahimi R; Hendoiee N; Abdollahi M
Daru; 2012 Nov; 20(1):75. PubMed ID: 23351929
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine-induced perinatal morbidity in a sheep model.
Domingues RR; Beard AD; Connelly MK; Wiltbank MC; Hernandez LL
Front Med (Lausanne); 2022; 9():955560. PubMed ID: 35991651
[TBL] [Abstract][Full Text] [Related]
18. Early Developmental Exposure to Fluoxetine and Citalopram Results in Different Neurodevelopmental Outcomes.
Liu K; Garcia A; Park JJ; Toliver AA; Ramos L; Aizenman CD
Neuroscience; 2021 Jul; 467():110-121. PubMed ID: 34048796
[TBL] [Abstract][Full Text] [Related]
19. Gestational Exposure to Serotonin Reuptake Inhibitors and Pregnancy Outcome; Exploring the Role of Bias and Confounders.
Koren G; Ornoy A
Curr Neuropharmacol; 2021; 19(12):2227-2232. PubMed ID: 33059578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
